Voyager Therapeutics’ Capsid License Agreement and Strategic Collaboration with Novartis

Wilmer Cutler Pickering Hale and Dorr represented Voyager Therapeutics, Inc. in the transaction.  Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced a strategic collaboration and capsid license agreement with...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Dalia’s Series A Financing

WilmerHale advised Dalia on the deal. Dalia, a recruitment marketing automation platform, announced the completion of its Series A financing round led by Lewis & Clark...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

CinCor Pharma’s $193.6 Million IPO

Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here